These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 28096785)

  • 1. Nutrients as novel therapeutic approaches for metabolic disturbances in polycystic ovary syndrome.
    Mansour A; Hosseini S; Larijani B; Mohajeri-Tehrani MR
    EXCLI J; 2016; 15():551-564. PubMed ID: 28096785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and future aspects of several adjunctive treatment strategies in polycystic ovary syndrome.
    Banaszewska B; Pawelczyk L; Spaczynski R
    Reprod Biol; 2019 Dec; 19(4):309-315. PubMed ID: 31606349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polycystic Ovary Syndrome.
    Azziz R
    Obstet Gynecol; 2018 Aug; 132(2):321-336. PubMed ID: 29995717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycystic ovary syndrome and metabolic syndrome.
    Ali AT
    Ceska Gynekol; 2015 Aug; 80(4):279-89. PubMed ID: 26265416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polycystic ovary syndrome and mitochondrial dysfunction.
    Zhang J; Bao Y; Zhou X; Zheng L
    Reprod Biol Endocrinol; 2019 Aug; 17(1):67. PubMed ID: 31420039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum Vitamin D Levels and Polycystic Ovary syndrome: A Systematic Review and Meta-Analysis.
    He C; Lin Z; Robb SW; Ezeamama AE
    Nutrients; 2015 Jun; 7(6):4555-77. PubMed ID: 26061015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of nutrient supplementation in the management of polycystic ovary syndrome-associated metabolic dysfunctions: A critical review.
    Günalan E; Yaba A; Yılmaz B
    J Turk Ger Gynecol Assoc; 2018 Nov; 19(4):220-232. PubMed ID: 30299265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacotherapeutic management of comorbid polycystic ovary syndrome and diabetes.
    Ortiz-Flores AE; Luque-Ramírez M; Escobar-Morreale HF
    Expert Opin Pharmacother; 2018 Dec; 19(17):1915-1926. PubMed ID: 30289728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Body composition and polycystic ovary syndrome].
    Zabuliene L; Tutkuviene J
    Medicina (Kaunas); 2010; 46(2):142-57. PubMed ID: 20440089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and management of polycystic ovary syndrome: a practical guide.
    Stankiewicz M; Norman R
    Drugs; 2006; 66(7):903-12. PubMed ID: 16740005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polycystic ovary syndrome in the Indian Subcontinent.
    Allahbadia GN; Merchant R
    Semin Reprod Med; 2008 Jan; 26(1):22-34. PubMed ID: 18181079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Therapeutic Approaches in Obesity and Metabolic Syndrome Associated with Polycystic Ovary Syndrome.
    Saleem F; Rizvi SW
    Cureus; 2017 Nov; 9(11):e1844. PubMed ID: 29344438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic consequences of polycystic ovary syndrome.
    Churchill SJ; Wang ET; Pisarska MD
    Minerva Ginecol; 2015 Dec; 67(6):545-55. PubMed ID: 26372304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polycystic ovary syndrome and metabolic comorbidities: therapeutic options.
    De Leo V; Musacchio MC; Palermo V; Di Sabatino A; Morgante G; Petraglia F
    Drugs Today (Barc); 2009 Oct; 45(10):763-75. PubMed ID: 20069140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pregnancy complications in women with polycystic ovary syndrome.
    Palomba S; de Wilde MA; Falbo A; Koster MP; La Sala GB; Fauser BC
    Hum Reprod Update; 2015; 21(5):575-92. PubMed ID: 26117684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome.
    Unfer V; Porcaro G
    Expert Rev Clin Pharmacol; 2014 Sep; 7(5):623-31. PubMed ID: 24898153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polycystic ovary syndrome: chemical pharmacotherapy.
    Rocca ML; Venturella R; Mocciaro R; Di Cello A; Sacchinelli A; Russo V; Trapasso S; Zullo F; Morelli M
    Expert Opin Pharmacother; 2015 Jun; 16(9):1369-93. PubMed ID: 26001184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implicating androgen excess in propagating metabolic disease in polycystic ovary syndrome.
    Kempegowda P; Melson E; Manolopoulos KN; Arlt W; O'Reilly MW
    Ther Adv Endocrinol Metab; 2020; 11():2042018820934319. PubMed ID: 32637065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical implications of polycystic ovary syndrome].
    Dravecká I
    Vnitr Lek; 2016; 62(5):392-7. PubMed ID: 27319232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acupuncture in polycystic ovary syndrome: current experimental and clinical evidence.
    Stener-Victorin E; Jedel E; Mannerås L
    J Neuroendocrinol; 2008 Mar; 20(3):290-8. PubMed ID: 18047551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.